0
0
San Francisco, May 2 – In a major breakthrough for Parkinson’s disease research, scientists at the University of California, San Francisco (UCSF) have announced that psilocybin-the psychoactive compound in “magic mushrooms”-may offer significant improvements in mood, cognition, and even motor symptoms for patients with the neurodegenerative disorder.
This pioneering pilot study marks the first time a psychedelic has been systematically tested on patients with any neurodegenerative disease. The results, published in Neuropsychopharmacology, exceeded researchers’ expectations: participants not only tolerated the treatment well, but also experienced sustained relief from mood dysfunction and improvements in movement-an uncommon outcome in Parkinson’s therapy.
Study Details and Outcomes
The UCSF study enrolled 12 patients with mild to moderate Parkinson’s disease, all of whom struggled with depression or anxiety-conditions that often precede and worsen motor symptoms in Parkinson’s. Participants received a low 10 mg dose of psilocybin, followed by a higher 25 mg dose two weeks later, each paired with psychotherapy sessions for preparation, support, and integration.
While some mild side effects such as anxiety and nausea were reported, none required medical intervention. Crucially, patients showed “clinically significant improvements” in mood, cognition, and motor function that persisted for weeks after the drug had left their systems.
“We are still in very early stages of this work, but this first study went well beyond what we expected,” said Dr. Ellen Bradley, the study’s lead author and associate director of UCSF’s Translational Psychedelic Research Program (TrPR).
Mood disorders like depression and anxiety are strong predictors of quality of life in Parkinson’s patients, often more so than physical symptoms. Traditional antidepressants frequently fail in this population, underscoring the urgent need for new therapeutic options.
How Psilocybin May Help
Researchers believe psilocybin may aid recovery through several mechanisms:
-
Enhancing neuroplasticity (the brain’s ability to form new connections)
-
Reducing brain inflammation
-
Improving emotional health, which can promote greater physical engagement and activity
“These results raise the exciting possibility that psilocybin may help the brain repair itself,” said Dr. Joshua Woolley, senior author and director of the TrPR Program at UCSF.
Next Steps: Larger Trials and Deeper Investigation
Buoyed by these promising results, UCSF and Yale University are launching a larger, randomized controlled trial involving 100 patients. The new study will include advanced neuroimaging and brain stimulation to better understand how psilocybin affects the brain and its potential to rewire neural circuits. The initiative is supported by the Michael J. Fox Foundation and an anonymous donor.
“The vast majority of brain diseases still lack interventions that change the course of illness. We can often treat the symptoms, but we don’t alter the trajectory or prevent decline. Now, that’s beginning to change,” Dr. Woolley noted.
Disclaimer:
Psilocybin remains a controlled substance and is not approved for routine clinical use in Parkinson’s disease. The findings described are from a small, early-stage clinical study. Larger, more rigorous trials are needed to confirm safety and efficacy. Patients should not attempt to self-medicate with psilocybin or related substances outside of approved clinical research settings.
Citations:
